Clinical Trials

Phase 3 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

NCT05700448 2026-02-05

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

150 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT06069830 2026-01-27

ENKTL

Phase NA Recruiting

89 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04509466 2024-03-07

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Phase 1/2 Terminated

41 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

54 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02733458 2021-09-14

GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

Phase NA Completed

52 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02631239 2021-08-25

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Phase 3 Unknown

256 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04999878 2021-08-11

RUE-DDGP

Phase 4 Unknown

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

15 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

264 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04676789 2020-12-21

SPENT

Lymphoma, Extranodal NK-T-Cell

NCT04405375 2020-05-28

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

29 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04337593 2020-04-07

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

20 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04096690 2020-03-11

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

22 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02359162 2018-05-09

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Phase 3 Terminated

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02533323 2018-05-09

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Phase 2 Terminated

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02825147 2017-11-14

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

Phase 2 Completed

40 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01991158 2016-06-14

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT02080234 2016-04-20

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

40 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01921790 2013-08-22

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT01667302 2013-03-05

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma